At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week
In Brief
A Phase 4 clinical trial evaluating Rebif Rebidose and Rebiject II for Multiple Sclerosis, Relapsing-Remitting. Completed, enrolled 97 participants across 21 sites.
Detailed Summary
This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS). Subjects will participate in the study for up to 10 weeks (including screening and treatment periods). The treatment period will last 8 weeks and include 12 self-injections using the Rebif® Rebidose® device and 12 self-injections using the Rebiject II® device.
Study Details
Timeline
Interventions
Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.